The content here is for informational purposes only, should not be taken as legal business,

tax, or investment advice, or be used to evaluate any investment or security and is not

directed at any investors or potential investors in any A16Z fund. For more details,

please see A16Z.com slash disclosures.

Hi, everyone. Welcome to the A6 and Z podcast.

I'm Sonal.

So today we have another one of our special episodes with more special guests that was

recorded during the recent JPM healthcare conference in San Francisco.

The topic is all about diagnosing and treating cancer in pets to humans, but we also go

into other topics relevant to all kinds of health care and

tech startup founders, from data network effects to real world evidence and science, to clinical

trials, to how to think about product and roadmap when building a bio company. So first,

our special guest is Amy Abernethy, who has been named the new principal deputy commissioner of the FDA,

the U.S. Food and Drug Administration pending ethics clearance. She is currently the chief medical and chief scientific officer

at Flatiron Health. And we also have Christina Lopez, CEO and co-founder of One Health, which

provides dogs access to the latest cancer treatments, and in doing so, contributes data to

developing better future therapies for humans. She's the first voice you'll hear. And finally,

we have A6 and Z general partner Jorge Condé of the BioFund, who will be moderating this episode,

which ends with the question of what does it take to build biocompanyes, but begins with a question about why

cancer and dogs and the link to humans. You know, dogs come from wolves. They co-evolved with us,

right? And similar to other animals, they are predisposed to cancer, as we are, very similar.

The idea there is certain litters that got bred, sadly got bred with their beauty and, you know,

...